NCT06936943 is a Phase 2 clinical trial of ONO-4538 in Richter's Transformation, sponsored by Ono Pharmaceutical Co., Ltd..

Who is sponsoring NCT06936943?

NCT06936943 is sponsored by Ono Pharmaceutical Co., Ltd..

What drugs are being tested in NCT06936943?

Interventions in NCT06936943: ONO-4538.

What condition does NCT06936943 study?

NCT06936943 studies Richter's Transformation.

Is NCT06936943 still recruiting?

NCT06936943 is currently recruiting now. Last updated 13 February 2026.

Last reviewed 2026-02-13 · How we verify

NCT06936943

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ONO-4538 Study in Patients With Richter's Transformation

Recruiting now Phase 2 Last updated 13 February 2026

What this trial tests

Phase 2 trial testing ONO-4538 in Richter's Transformation in 14 participants. Currently enrolling.

Timeline

19 November 2025

Primary endpoint
31 July 2029

31 July 2030

Quick facts

Lead sponsor	Ono Pharmaceutical Co., Ltd.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	14
Start date	19 November 2025
Primary completion	31 July 2029
Estimated completion	31 July 2030
Sites	10 locations across Japan

Drugs / interventions tested

ONO-4538 — full drug profile →

Conditions studied

Richter's Transformation — all drugs for Richter's Transformation →

Sponsor

Ono Pharmaceutical Co., Ltd.

Who can join

18 and older, any sex, with Richter's Transformation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigate the efficacy and safety of ONO-4538 in patients with Richter's transformation

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of ONO-4538

Trials testing the same drug.

NCT06622941 — Study to ONO-4538 in Patients With Rhabdoid Tumor · Phase 2 · recruiting
NCT06532331 — A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, · Phase 1 · active not recruiting
NCT06535009 — Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors · Phase 1 · terminated
NCT06540261 — The Study of ONO-7913, ONO-4538 and the Standard of Care as First-line Treatment in Patients Colorectal Cancer · Phase 1 · active not recruiting
NCT06532344 — An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard · Phase 1 · active not recruiting

Other recruiting trials for Richter's Transformation

Currently open trials in the same condition.

NCT06043674 — Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transfor · Phase 2 · recruiting
NCT05294731 — Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Deg · Phase 1, PHASE2 · recruiting
NCT03162536 — A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK- · Phase 1, PHASE2 · active not recruiting

Other Ono Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07169708 — A Retrospective Observational Study of Nivolumab in Combination With Chemotherapy as Neoadjuvant Therapy for Resectable · not yet recruiting
NCT06948448 — A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an · Phase 2 · recruiting
NCT07198087 — A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impa · Phase 1 · active not recruiting
NCT06803823 — A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia · Phase 2 · recruiting
NCT06708416 — A Study of ONO-1110 in Patients With Postherpetic Neuralgia · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06936943 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ono Pharmaceutical Co., Ltd.
Last refreshed: 13 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06936943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing